Exploring of Mutational Landscape and Prognostic Factors in Intermediate-Risk Cytogenetic Acute Myel

来源 :2019中国肿瘤学大会 | 被引量 : 0次 | 上传用户:luckycpw
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Objective Acute myeloid leukemia(AML)is a common hematologic malignance with strong heterogeneity,different cytogenetic and molecular defects present completely different clinical properties and therapeutic response.
其他文献
Objective Ewing sarcoma(ES)is a second-most-common malignant pediatric tumor from bone and soft tissue with high metastatic incidence,and it occurs at any age with a peak during 10-20 years old.
Objective This study aimed to identify reliable and distinct immune-associated gene signatures for robust classification and survival prediction of patients with CLL.
Objective Glioma is characterized as a lethal type of brain tumor in the adult,among which glioblastoma(GBM)is the most malignant one.
Objective Chemotherapy constitutes the conventional treatments for breast cancer and produces abundant benefits for both early-and advanced-stage breast cancers.
Objective The Notch signaling regulates numerous cell growth,differentiation,and death.In particular,transmembrane receptor Delta-like 4(Dll4)has raised extensive interests since it is absolutely requ
Objective Fatty acid is the main organic molecule composing the cell membrane,and thus is critical with both the energy and materials necessary for the biosynthesis of signaling molecule.
目的 肺癌是全世界癌症相关死亡最常见的原因,其中超过85%的肺癌是非小细胞肺癌。据统计,高达69%的晚期非小细胞肺癌患者可能有一个潜在的可操作的分子靶点。临床上成纤维细胞生长因子受体1(FGFR1)和SOX2 高表达与非小细胞肺癌患者生存时间短呈正相关。
Objective GBC is the most common malignancy of the biliary tracts1.The incidence and distribution of GBC differ across worldwide.For example,the prevalence of GBC in South and East Asia is considerabl
目的 目的:研究胶质瘤中TERT 突变、染色体1p/19q 联合缺失与临床预后的关系。方法 方法:采用荧光原位杂交法(Fluorescence in situ hybridization,FISH)检测1p/19q联合缺失情况;采用PCR 技术检测TERT 基因突变;同时收集免疫组化方法对IDH1、MGMT、Ki-67 表达情况的检测结果。
Objective Lung cancer is the leading cause of cancer death worldwide.In the past decades,significant improvements have been made for lung cancer treatment,based on discoveries of molecular biomarkers